Graves' DiseasePhase 2NCT06727604
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
A Phase 2 study testing IMVT-1402 in people with Graves' Disease, run by Immunovant Sciences GmbH at 134 sites in 10 countries.
Trial summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Graves' Disease
- What is being tested?
- IMVT-1402
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- 134 sitesin 10 countries
- Study dates
- 17 Dec 2024to Jun 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
- Male or female participants aged ≥ 18 years.
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
- Other, more specific inclusion criteria are defined in the protocol.
Who cannot join
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
- Additional exclusion criteria are defined in the protocol.
Trial locations and contacts
134 sites in 10 countries. Contact the study team or a site near you to ask about taking part.
134 sites in 10 countries
United States64 sites, 55 recruiting
- Recruiting
Site Number - 1051
Asheville, North Carolina, 28803
- Recruiting
Site Number - 1038
Atlanta, Georgia, 30318
- Recruiting
Site Number - 1002
Austin, Texas, 78731
- Recruiting
Site Number - 1023
Baltimore, Maryland, 21287
- Recruiting
Site Number - 1067
Bellaire, Texas, 77401
- Recruiting
Site Number - 1026
Boston, Massachusetts, 02114
- Recruiting
Site Number - 1045
Bowling Green, Kentucky, 42101
- Recruiting
Site Number - 1057
Canton, Ohio, 44718
- Recruiting
Site Number - 1042
Chattanooga, Tennessee, 37421
- Recruiting
Site Number - 1029
Clearwater, Florida, 33756
- Recruiting
Site Number - 1019
Dallas, Texas, 75208
- Withdrawn
Site Number - 1031
Dallas, Texas, 75231
- Recruiting
Site Number - 1013
Englewood, Colorado, 80113
- Recruiting
Site Number - 1018
Farmington Hills, Michigan, 48334
- Recruiting
Site Number - 1069
Flint, Michigan, 48532
- Recruiting
Site Number - 1054
Florence, Kentucky, 41042
- Recruiting
Site Number - 1068
Gulfport, Mississippi, 39501
- Recruiting
Site Number - 1071
Houston, Texas, 77089
- Withdrawn
Site Number - 1025
Houston, Texas, 77095
- Recruiting
Site Number - 1061
Huntington Beach, California, 92647
- Recruiting
Site Number - 1027
Indianapolis, Indiana, 46202
- Recruiting
Site Number - 1055
Jacksonville, Florida, 32204-1177
- Recruiting
Site Number - 1056
Jacksonville, Florida, 32216
- Recruiting
Site Number - 1041
Kansas City, Kansas, 66210
- Recruiting
Site Number - 1007
Las Vegas, Nevada, 89148
- Recruiting
Site Number - 1001
Los Angeles, California, 90033
- Recruiting
Site Number - 1047
Los Angeles, California, 90095
- Recruiting
Site Number - 1053
Macon, Georgia, 31210
- Recruiting
Site Number - 1004
Mesquite, Texas, 75149
- Recruiting
Site Number - 1063
Metairie, Louisiana, 70006
- Recruiting
Site Number - 1028
Miami, Florida, 33136
- Recruiting
Site Number - 1065
Miami, Florida, 33186
- Recruiting
Site Number - 1050
Monroe, New York, 10950
- Recruiting
Site Number - 1066
Nashville, Tennessee, 37203
- Recruiting
Site Number - 1049
Nashville, Tennessee, 37212
- Recruiting
Site Number - 1022
New Orleans, Louisiana, 70112
- Recruiting
Site Number - 1010
Newark, Delaware, 19713
- Recruiting
Site Number - 1064
Ocoee, Florida, 34761
- Recruiting
Site Number - 1017
Omaha, Nebraska, 68105
- Recruiting
Site Number - 1062
Orange, California, 92868
- Withdrawn
Site Number - 1011
Orlando, Florida, 32819
- Withdrawn
Site Number - 1033
Philadelphia, Pennsylvania, 19140
- Withdrawn
Site Number - 1032
Phoenix, Arizona, 85006
- Recruiting
Site Number - 1036
Phoenix, Arizona, 85015
- Recruiting
Site Number - 1016
Port Charlotte, Florida, 33952
- Recruiting
Site Number - 1003
Portland, Oregon, 97035
- Recruiting
Site Number - 1043
Pottstown, Pennsylvania, 19464
- Recruiting
Site Number - 1008
Rochester, Minnesota, 55905
- Recruiting
Site Number - 1009
Round Rock, Texas, 78681
- Recruiting
Site Number - 1046
Sacramento, California, 95816
- Recruiting
Site Number - 1030
Salt Lake City, Utah, 84108
- Recruiting
Site Number - 1014
San Antonio, Texas, 78215
- Recruiting
Site Number - 1052
San Antonio, Texas, 78240
- Recruiting
Site Number - 1034
San Francisco, California, 94143
- Recruiting
Site Number - 1070
Sandy City, Utah, 84093
- Withdrawn
Site Number - 1035
Santa Clarita, California, 91321
- Recruiting
Site Number - 1048
Shreveport, Louisiana, 71103
- Withdrawn
Site Number - 1020
Stockbridge, Georgia, 30281
- Recruiting
Site Number - 1015
Summerville, South Carolina, 29485
- Recruiting
Site Number - 1005
Torrance, California, 90502
- Withdrawn
Site Number - 1006
Walnut Creek, California, 94598
- Recruiting
Site Number - 1040
Washington D.C., District of Columbia, 20010
- Withdrawn
Site Number - 1012
West Palm Beach, Florida, 33401
- Recruiting
Site Number - 1060
Wilmington, North Carolina, 28401
United Kingdom14 sites, 14 recruiting
- Recruiting
Site Number - 7013
Birmingham, England, B15 2TT
- Recruiting
Site Number - 7012
Bristol, England, BS10 5NB
- Recruiting
Site Number - 7014
Cambridge, London, CB2 0QQ
- Recruiting
Site Number - 7002
Cardiff, CF14 4XW
- Recruiting
Site Number - 7011
Coventry, England, CV2 2DX
- Recruiting
Site Number - 7008
Edinburgh, EH16 4SA
- Recruiting
Site Number - 7005
Huddersfield, HD3 3EA
- Recruiting
Site Number - 7004
Hull, HU6 7RX
- Recruiting
Site Number - 7007
London, England, NW1 2PG
- Recruiting
Site Number - 7003
London, SE5 9RS
- Recruiting
Site Number - 7006
Manchester, M20 4BX
- Recruiting
Site Number - 7001
Newcastle upon Tyne, NE1 4LP
- Recruiting
Site Number - 7009
Norwich, NR4 7UY
- Recruiting
Site Number - 7010
Nuneaton, CV10 7DJ
Italy12 sites, 12 recruiting
- Recruiting
Site Number - 6004
Bologna, 40138
- Recruiting
Site Number - 6012
Cagliari, 09124
- Recruiting
Site Number - 6011
Genova, 16132
- Recruiting
Site Number - 6002
Milan, 20122
- Recruiting
Site Number - 6009
Milan, 20162
- Recruiting
Site Number - 6007
Milan, 20149
- Recruiting
Site Number - 6010
Naples, 80131
- Recruiting
Site Number - 6003
Pisa, 56124
- Recruiting
Site Number - 6001
Pisa, 56126
- Recruiting
Site Number - 6005
Roma, 00189
- Recruiting
Site Number - 6013
Siena, 53100
- Recruiting
Site Number - 6008
Varese, 21100
Georgia11 sites, 11 recruiting
- Recruiting
Site Number - 8002
Batumi, 6000
- Recruiting
Site Number - 8007
Batumi, 6010
- Recruiting
Site Number - 8006
Kutaisi, 4600
- Recruiting
Site Number - 8008
Marneuli, 3000
- Recruiting
Site Number - 8009
Tbilisi, 0112
- Recruiting
Site Number - 8004
Tbilisi, 0144
- Recruiting
Site Number - 8005
Tbilisi, 0144
- Recruiting
Site Number - 8001
Tbilisi, 0159
- Recruiting
Site Number - 8003
Tbilisi, 0159
- Recruiting
Site Number - 8011
Tbilisi, 0159
- Recruiting
Site Number - 8010
Tbilisi, 0177
Spain9 sites, 9 recruiting
- Recruiting
Site Number - 7104
Badalona, Barcelona, 08916
- Recruiting
Site Number - 7109
Barcelona, 08035
- Recruiting
Site Number - 7103
Barcelona, 08036
- Recruiting
Site Number - 7102
Córdoba, 14004
- Recruiting
Site Number - 7106
Granada, 18014
- Recruiting
Site Number - 7105
Madrid, 28006
- Recruiting
Site Number - 7107
Pamplona, 31008
- Recruiting
Site Number - 7108
Pamplona, 31008
- Recruiting
Site Number - 7101
Seville, 41009
Poland8 sites, 8 recruiting
- Recruiting
Site Number - 3006
Gliwice, 44-102
- Recruiting
Site Number - 3002
Krakow, 30-074
- Recruiting
Site Number -3003
Krakow, 30-688
- Recruiting
Site Number - 3005
Lublin, 20-400
- Recruiting
Site Number - 3008
Lublin, 20-607
- Recruiting
Site Number - 3004
Lublin, 91-495
- Recruiting
Site Number - 3007
Poznan, 60-354
- Recruiting
Site Number - 3001
Warsaw, 00-0189
Hungary6 sites, 6 recruiting
- Recruiting
Site Number - 7558
Békéscsaba, 5600
- Recruiting
Site Number - 7554
Budapest, 1036
- Recruiting
Site Number - 7556
Budapest, 1083
- Recruiting
Site Number - 7557
Debrecen, 4032
- Recruiting
Site Number - 7551
Pécs, 7623
- Recruiting
Site Number - 7552
Szeged, 6725
Germany5 sites, 5 recruiting
- Recruiting
Site Number - 6505
Dresden, Saxony, 01307
- Recruiting
Site Number - 6503
Munich, 80336
- Recruiting
Site Number - 6508
Munich, 81667
- Recruiting
Site Number - 6502
Schwerin, 19049
- Recruiting
Site Number - 6507
Würzburg, 97080
Belgium3 sites, 3 recruiting
- Recruiting
Site Number - 5303
Antwerp, 2820
- Recruiting
Site Number - 5301
Bruges, 80000
- Recruiting
Site Number - 5302
Brussels, 1070
Puerto Rico2 sites, 1 recruiting
- Recruiting
Site Number - 1058
San Juan, 00907
- Withdrawn
Site Number - 1037
San Juan, 00921-3313
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
- Conditions
- Graves' Disease
- Being tested
- IMVT-1402, Placebo
- Keywords
- IMVT-1402, Anti Thyroid Drug, Hyperthyroidism, Autoimmune thyroid disease, Imeroprubart
- Medical subject headings
- Graves Disease, Hyperthyroidism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IMVT-1402Drug
600 mg SC QW for 52 weeks
IMVT-1402Drug
600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
PlaceboDrug
SC QW for 52 weeks
| Study group | Role | What they receive |
|---|---|---|
| Group 1 Period 1 and 2: IMVT-1402 | Experimental | Not described Receives: Drug: IMVT-1402 |
| Group 2 Period 1 and 2: IMVT-1402 | Experimental | Not described Receives: Drug: IMVT-1402 |
| Group 2 Period 1: IMVT-1402 and Period 2: Placebo | Experimental | Not described Receives: Drug: IMVT-1402 |
| Group 3 Period 1 and 2: Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26
Measured: Week 26
Secondary outcomes (11)
Percentage of participants who are euthyroid and off ATD at Week 52
Measured: Week 52
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 52
Measured: Week 52
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 52 to Week 78
Measured: Week 78
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 52 to Week 104
Measured: Week 104
Percentage of participants who have a TRAb value a specified amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 26 to Week 52
Measured: Week 52
Percentage of participants who have a TRAb value a specific amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 26 to Week 78
Measured: Week 78
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 2 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Measured: Week 2
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 4 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Measured: Week 4
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 26
Measured: Week 26
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 26
Measured: Week 26
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 52
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2024
- Study start17 Dec 2024
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Graves' DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Immunovant Sciences GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06727604
- Sponsor's protocol ID
- IMVT-1402-2502
- Other IDs
- 2024-516020-33-00
- Status last verified
- Aug 2026
- First submitted
- 9 Dec 2024
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
- ClinicalTrials.gov ID
- NCT06727604
- Acronym / sponsor ID
- IMVT-1402-2502
- Conditions
- Graves' Disease
- Keywords
- IMVT-1402, Anti Thyroid Drug, Hyperthyroidism, Autoimmune thyroid disease, Imeroprubart
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Immunovant Sciences GmbHIndustry (pharma, biotech, devices)
- Study start
- 17 Dec 2024 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 11 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1 Period 1 and 2: IMVT-1402 | Experimental | Drug: IMVT-1402 |
| Group 2 Period 1 and 2: IMVT-1402 | Experimental | Drug: IMVT-1402 |
| Group 2 Period 1: IMVT-1402 and Period 2: Placebo | Experimental | Drug: IMVT-1402 |
| Group 3 Period 1 and 2: Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
- Male or female participants aged ≥ 18 years.
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
- Other, more specific inclusion criteria are defined in the protocol.
Key exclusion criteria (4 listed)
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
- Additional exclusion criteria are defined in the protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IMVT-1402600 mg SC QW for 52 weeks | Drug | Group 1 Period 1 and 2: IMVT-1402, Group 2 Period 1 and 2: IMVT-1402 |
| IMVT-1402600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks | Drug | Group 2 Period 1: IMVT-1402 and Period 2: Placebo |
| PlaceboSC QW for 52 weeks | Drug | Group 3 Period 1 and 2: Placebo |
Primary outcome
Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26
Time frame: Week 26
11 secondary outcomes
Percentage of participants who are euthyroid and off ATD at Week 52
Time frame: Week 52
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 52
Time frame: Week 52
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 52 to Week 78
Time frame: Week 78
Percentage of participants who are euthyroid and off ATD at Week 52 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 52 to Week 104
Time frame: Week 104
Percentage of participants who have a TRAb value a specified amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 6 months from Week 26 to Week 52
Time frame: Week 52
Percentage of participants who have a TRAb value a specific amount and are euthyroid and off ATD at Week 26 and remain euthyroid, off IMVT-1402, and off ATD for 12 months from Week 26 to Week 78
Time frame: Week 78
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 2 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Time frame: Week 2
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN at Week 4 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline
Time frame: Week 4
Percentage of participants who are euthyroid, off ATD, and seronegative for TRAb at Week 26
Time frame: Week 26
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 26
Time frame: Week 26
Percentage of participants who have T3 (Total T3 or FT3) and FT4 < ULN and are off ATD at Week 52
Time frame: Week 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Graves' Disease
Not yet recruiting
Impact of Restrictive Diets on Inflammation and Quality of Life in Autoimmune Thyroiditis
Thyroid Autoimmune Disease, Hashimoto's Thyroiditis
RecruitingPhase 3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Graves' Disease, Graves Disease
RecruitingPhase 3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Graves Disease
Active, not recruitingPhase 4
Hydroxychloroquine in Mild Graves' Orbitopathy
Graves Ophthalmopathy
RecruitingPhase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
134 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing IMVT-1402 in people with Graves' Disease, run by Immunovant Sciences GmbH at 134 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 134 sites in United States, United Kingdom, Italy, Georgia, Spain and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Central Study Contact (18007970414, clinicaltrials@immunovant.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26 (time frame: Week 26). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.